JPMorgan upgraded UCB to Overweight from Neutral with a price target of EUR 200, up from EUR 150. The analyst expects an expected acceleration in Bimzelx growth driven by new indications and atopic dermatitis.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UCBJF:
- UCB price target raised to EUR 200 from EUR 150 at Deutsche Bank
- UCB price target raised to EUR 175 from EUR 160 at Barclays
- UCB upgraded to Outperform from Neutral at Oddo BHF
- UCB price target raised to EUR 150 from EUR 140 at Deutsche Bank
- UCB price target raised to EUR 160 from EUR 150 at Barclays
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue